Acromegaly: Novel Therapeutic Options to Alleviate Treatment Burden and Improve Patient Quality of Life

1.25 CME
1.25 ABIM MOC
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Acromegaly: Novel Therapeutic Options to Alleviate Treatment Burden and Improve Patient Quality of Life

Overview

Provider Statement

This continuing medical education activity is provided by The Endocrine Society

Educational Partner: vindico


Support Statement

This activity is supported by an educational grant from Chiasma, Inc.


Activity Description

Acromegaly, a condition caused by an increased release of growth hormone (GH) by the pituitary gland, is characterized by tissue overgrowth, presenting with facial and extremity enlargements as well as systemic comorbidities that are associated with increased mortality. While it is considered rare, the prevalence of acromegaly has been increasing, due to more disease awareness. Patients with acromegaly experience diminished quality of life (QoL). Surgery, medical therapy, and radiation therapy are utilized as treatment for the disorder, but approved treatment options do not always confer improved QoL or complete symptom relief. In this CME activity, expert faculty provide an update on the current state-of-the-art management of patients with acromegaly, including a closer look at conventional treatments as well as newly approved and emerging therapies to alleviate treatment burden and improve patient QoL.


Target Audience

The intended audience for this activity is endocrinologists and other health care professionals involved in the management of patients with acromegaly.

Learning Objective

Upon successful completion of this activity, participants should be better able to:

  • Evaluate strategies to improve patient recognition and diagnosis based on the pathophysiology and clinical symptomology of acromegaly.
  • Describe the common comorbidities associated with acromegaly and the burden on patient quality of life (QoL) despite endocrine control.
  • Examine the most recent clinical evidence regarding the safety and efficacy of currently approved and emerging treatment options for the management of patients with acromegaly.
  • Review the importance of continued monitoring of patients with acromegaly and improved provider-patient communication to ensure symptom control and minimizing the treatment burden and QoL burden.

Activity Chair

Eliza B. Geer, MD
Medical Director
Multidisciplinary Pituitary and Skull Base Tumor Center
Associate Attending, Endocrinology Service
Memorial Sloan Kettering Cancer Center
New York, NY


Faculty

Maria Fleseriu, MD, FACE
Professor
Director Pituitary Center
Oregon Health & Science University
Portland, OR

Adriana Ioachimescu, MD, PhD
Professor of Medicine (Endocrinology) and Neurosurgery
Emory University School of Medicine
Co-Director, The Emory Pituitary Center
Consulting Editor, Endocrinology and Metabolism Clinics
Atlanta, GA


Reviewer

Katherine Araque, MD
Director of Endocrinology,
Pacific Neuroscience Institute
Santa Monica, CA


Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

The Endocrine Society designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, May 7, 2021, through May 6, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Endocrine Society will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s)

Maria Fleseriu, MD
Consulting Fee: Chiasma, Crinetics, Ipsen, Pfizer, Recordati
Grant Recipient: Chiasma, Crinetics, Ionis

Eliza B. Geer, MD
Consulting Fee: Chiasma, Crinetics
Contracted Research: Chiasma, Ionis

Adriana Ioachimescu, MD
Consulting Fee: Tiburio
Contracted Research: Chiasma, Recordati
Advisory Board: Recordati

Reviewers report the following relationship(s)

Katherine Araque, MD
No relevant financial relationships to disclose.

The Endocrine Society and Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at The Endocrine Society.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact The Endocrine Society at education.endocrine.org/contact.


Technical Questions?

Contact Vindico Medical Education at CME@VindicoCME.com